Prazosin vs Doxazosin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

alpha-Adrenergic Blocker

Prazosin

First FDA approval: 1989-02-28

alpha-Adrenergic Blocker

Doxazosin

Brand: Cardura

First FDA approval: 2000-10-18

Lowest NADACAcquisition cost floor across all NDCs

$0.085Per unit

$0.069Per unit

Average NADACAcross all dosage forms and strengths

$0.107Up to $0.146

$0.164Up to $6.97

Generic manufacturersActive ANDA holders — FDA Orange Book

927 total ANDAs filed

936 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$37.6MFull year

$54.9MFull year

Part D claims (CY24)Total fills, all strengths

2.0M410K beneficiaries

3.3M996K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$19Per claim, all NDCs

$17Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes9 manufacturers